Mesothelioma Treatment

Mesothelioma Treatment Overview
Multimodal Treatment Approaches
Category	Medical / Treatment
FDA-Approved Regimens	3 (systemic)
First-Line Immunotherapy	Nivolumab + Ipilimumab
First-Line Chemotherapy	Pemetrexed + Cisplatin
Preferred Surgery	Pleurectomy/Decortication
Immunotherapy 5-Year OS	14% (vs. 6% chemo)
Active Clinical Trials	93+ recruiting (2026)
Current Guidelines	ASCO 2025 / NCCN v1.2025
Free Case Review →

Executive Summary

Treatment for mesothelioma has undergone its most significant transformation in two decades. The 2025 ASCO guideline update, informed by 110 peer-reviewed studies, established three first-line systemic regimens for pleural mesothelioma: platinum-pemetrexed chemotherapy, nivolumab plus ipilimumab immunotherapy, and pembrolizumab plus chemotherapy. Five-year data from the CheckMate 743 trial, published in February 2026, confirmed that immunotherapy more than doubles the five-year survival rate compared to chemotherapy alone (14% vs. 6%), with 17% of immunotherapy responders maintaining ongoing responses at five years versus 0% in the chemotherapy arm.

The surgical landscape has shifted decisively toward lung-sparing pleurectomy/decortication (P/D) over the more aggressive extrapleural pneumonectomy (EPP), with a 2025 meta-analysis demonstrating a mean survival advantage of 7 months for P/D. However, the MARS 2 trial raised fundamental questions about the benefit of surgery at all, finding that extended P/D plus chemotherapy produced worse survival than chemotherapy alone in an unselected population. The ASCO 2025 guidelines now restrict surgical candidacy to highly selected patients with early-stage epithelioid disease.

Several novel treatment modalities are advancing through the pipeline, including ADI-PEG 20 arginine depletion therapy (BLA under FDA review), tumor treating fields (FDA-approved under Humanitarian Device Exemption), and mesothelin-targeted CAR-T cell therapy showing a 72% response rate in early-phase trials. For peritoneal mesothelioma, cytoreductive surgery with heated intraperitoneal chemotherapy (CRS-HIPEC) achieves a median survival of 53 months and remains the standard of care at experienced centers.

Early integration of palliative care is now recommended by all major oncology organizations, with evidence demonstrating improved quality of life and potentially extended survival when specialist palliative services begin at diagnosis rather than at end of life.

At-a-Glance

Mesothelioma treatment at a glance:

• Immunotherapy doubles five-year survival over chemotherapy — CheckMate 743 five-year data show 14% of immunotherapy patients alive at five years versus 6% on chemotherapy, with the benefit most striking in non-epithelioid disease (12% vs. 1%)
• Three FDA-approved first-line systemic regimens exist as of 2026 — cisplatin-pemetrexed (2004), nivolumab-ipilimumab (2020), and pembrolizumab plus pemetrexed-platinum (September 2024)
• P/D is now preferred over EPP for surgical candidates — pleurectomy/decortication achieves comparable oncologic outcomes with 3% operative mortality versus 3.8-7% for extrapleural pneumonectomy
• Surgery is restricted to highly selected patients — ASCO 2025 recommends cytoreduction only for early-stage (T1-3N0) epithelioid tumors and explicitly opposes surgery for sarcomatoid disease
• CRS-HIPEC transforms peritoneal mesothelioma outcomes — cytoreductive surgery with heated intraperitoneal chemotherapy achieves 53-month median survival versus approximately 12 months with systemic chemotherapy alone
• Pembrolizumab-chemo achieves 52% response rate — KEYNOTE-483 showed pembrolizumab plus chemotherapy nearly doubles objective response rate compared to chemotherapy alone (52% vs. 29%)
• Radiation plays a role primarily after surgery or for symptom relief — the SMART protocol achieves 65.9-month median survival in selected epithelioid node-negative patients, while palliative radiation reduces pain in 47% of patients
• CAR-T cell therapy shows early promise — mesothelin-targeted CAR-T cells delivered intrapleurally with pembrolizumab achieved a 72% response rate in 11 mesothelioma patients at Memorial Sloan Kettering
• Early palliative care extends survival in lung cancer — the Temel landmark study demonstrated a 2.7-month survival benefit and reduced depression when palliative care begins at diagnosis
• Treatment selection depends on histology — non-epithelioid patients should receive immunotherapy first-line; chemotherapy alone should not be offered for sarcomatoid or biphasic disease unless immunotherapy is contraindicated

Key Facts

Measure	Finding (Source)
CheckMate 743 Five-Year OS	14% immunotherapy vs. 6% chemotherapy; 5-year PFS 8% vs. 0%; HR 0.74 — Baas et al., JCO 2026, n=605
KEYNOTE-483 Median OS	17.3 months pembrolizumab-chemo vs. 16.1 months chemo alone; ORR 52% vs. 29%; 3-year OS 25% vs. 17% — n=440
EMPHACIS Chemotherapy Survival	12.1 months cisplatin-pemetrexed vs. 9.3 months cisplatin alone; ORR 41.3% vs. 16.7% — Vogelzang et al., JCO 2003, n=448
P/D vs. EPP Survival Advantage	Mean 7.01 months P/D advantage (95% CI: 1.15-12.86, p=0.018) — 2025 systematic review and meta-analysis of 24 studies
MARS 2 Trial Result	Extended P/D + chemo: 19.3 months vs. chemo alone: 24.8 months (HR 1.28, p=0.032) — n=335, Lancet Resp Med 2024
CRS-HIPEC Peritoneal Survival	Median OS 53 months; 5-year survival 47%; CC-0 resection >94 months — Yan et al., n=405, 8 centers
SMART Protocol Median OS	65.9 months in epithelioid N0 patients; 36 months overall — Cho et al., Lancet Oncology 2021, n=96
STELLAR Trial TTFields Survival	Median OS 18.2 months; disease control rate 97%; 2-year survival 41.9% — n=80
MSK CAR-T Response Rate	72% ORR with mesothelin CAR-T + pembrolizumab in 11 mesothelioma patients; 2 complete metabolic responses
Non-Epithelioid Immunotherapy Benefit	5-year OS 12% vs. 1% (HR 0.48) for sarcomatoid/biphasic with immunotherapy vs. chemotherapy
ADI-PEG 20 ATOMIC-Meso	Median OS 9.3 vs. 7.6 months; PFS HR 0.66 (34% risk reduction); 3-year survival quadrupled — non-epithelioid patients
ASCO 2025 Guideline Scope	110 studies reviewed; 3 first-line regimens; surgery restricted to T1-3N0 epithelioid; BAP1 germline testing recommended for all patients

What Are the FDA-Approved Treatments for Mesothelioma?

As of early 2026, three systemic treatment regimens have received FDA approval specifically for pleural mesothelioma, along with one device-based therapy approved under the Humanitarian Device Exemption pathway:

Regimen	Year Approved	Trial Basis	Median OS
Cisplatin + Pemetrexed	February 2004	EMPHACIS	12.1 months
Nivolumab + Ipilimumab	October 2020	CheckMate 743	18.1 months
Pembrolizumab + Pemetrexed + Platinum	September 2024	KEYNOTE-483	17.3 months
TTFields + Chemotherapy (HDE)	May 2019	STELLAR	18.2 months

The 2025 ASCO guideline update recommends treatment selection based primarily on histologic subtype. For non-epithelioid (sarcomatoid and biphasic) disease, ipilimumab plus nivolumab is the preferred first-line regimen. Chemotherapy alone should not be offered for non-epithelioid mesothelioma unless immunotherapy is contraindicated. For epithelioid disease, all three systemic regimens are recommended options.

How Does Surgery Treat Mesothelioma?

Surgery for mesothelioma aims to remove as much visible tumor as possible (macroscopic complete resection) and is performed within multimodal treatment protocols that combine surgery with chemotherapy, immunotherapy, and/or radiation therapy. The two principal curative-intent procedures for pleural mesothelioma are pleurectomy/decortication and extrapleural pneumonectomy.

Pleurectomy/Decortication (P/D)

P/D is a lung-sparing procedure that removes the diseased pleural surfaces (parietal and visceral pleura) while preserving the underlying lung. Extended P/D additionally removes the pericardium and/or diaphragm when involved by tumor. A 2025 systematic review and meta-analysis of 24 studies demonstrated that P/D achieves a mean survival advantage of 7.01 months over EPP (95% CI: 1.15-12.86; p=0.018), with an operative mortality of 0-4% compared to 4-15% for EPP.

The 2025 ASCO and NCCN guidelines now explicitly recommend P/D as the first-choice surgical approach due to decreased operative and long-term risk. EPP may still be offered to highly selected patients at experienced centers of excellence.

Extrapleural Pneumonectomy (EPP)

EPP is a radical procedure that removes the entire affected lung along with the parietal and visceral pleura, ipsilateral pericardium, and ipsilateral diaphragm. Although EPP was historically the standard curative-intent operation, evidence has shifted against its routine use. The procedure carries an operative mortality of 3.8-7% at experienced centers and results in significant loss of pulmonary function and quality of life. A retrospective analysis of 663 patients found that P/D achieved a median survival of 16 months compared to 12 months for EPP, with lower distant recurrence rates (35% vs. 66%).

The MARS 2 Trial and Surgical Controversy

The phase III MARS 2 trial, the largest surgical trial in mesothelioma history with 335 patients across 26 UK hospitals, challenged the role of surgery in mesothelioma management. Extended P/D plus chemotherapy produced worse median survival than chemotherapy alone (19.3 vs. 24.8 months; HR 1.28, p=0.032) with a 9% 90-day surgical mortality.

However, these results have been contested by high-volume surgical centers. A 2026 Mount Sinai study of 71 patients undergoing P/D reported 0% 30-day mortality and 4.2% 90-day mortality. The ASCO 2025 guidelines take a nuanced position: surgical cytoreduction should not be routinely offered based solely on anatomic resectability, but may be offered to highly selected patients with clinical early-stage (T1-3N0) epithelioid tumors at centers with demonstrated expertise.

CRS-HIPEC for Peritoneal Mesothelioma

For peritoneal mesothelioma, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) represents the established standard of care. The landmark multicenter analysis of 405 patients across 8 centers reported a median survival of 53 months, 3-year survival of 60%, and 5-year survival of 47%. Complete cytoreduction (CC-0, no visible residual disease) is the strongest predictor of outcome, with median survival exceeding 94 months compared to only 12 months for CC-3 resections.

Who Is a Candidate for Mesothelioma Surgery?

Per the ASCO 2025 guidelines, surgical candidacy is restricted to:

• Patients with epithelioid histology only (sarcomatoid patients should not be offered maximal surgical cytoreduction)
• Clinical early-stage disease: T1-3, N0 (no lymph node involvement)
• Adequate performance status (ECOG 0-1) and cardiopulmonary function
• Treatment at centers of excellence with demonstrated surgical expertise
• No extrathoracic disease, contralateral pleural involvement, or peritoneal disease

For more detailed information, see Mesothelioma Surgery Overview and Mesothelioma Surgery Recovery.

How Does Chemotherapy Treat Mesothelioma?

Chemotherapy remains a cornerstone of mesothelioma treatment and the backbone of several first-line regimens. The cisplatin-pemetrexed doublet, approved in February 2004 based on the EMPHACIS trial, was the first FDA-approved treatment specifically for mesothelioma.

First-Line Chemotherapy Regimens

Cisplatin + Pemetrexed: The standard chemotherapy regimen achieves a 41.3% response rate and median survival of 12.1 months (vs. 9.3 months with cisplatin alone). Administered every 21 days for 4-6 cycles with folic acid and vitamin B12 supplementation to reduce toxicity.

Carboplatin Substitution: Carboplatin (AUC 5) may be substituted for cisplatin in patients who cannot tolerate cisplatin's renal toxicity. Real-world data from a 787-patient cohort showed comparable 8-month median survival regardless of platinum agent, with carboplatin causing significantly less kidney damage (GFR decline from 85 to 75 vs. 85 to 58 mL/min).

Bevacizumab Addition: The MAPS trial demonstrated that adding bevacizumab to cisplatin-pemetrexed improved median survival from 16.1 to 18.8 months (HR 0.77, p=0.017) in epithelioid-predominant disease, though at increased cost and risk of vascular events.

Second-Line Chemotherapy

For patients progressing after first-line treatment, options include vinorelbine, gemcitabine, or gemcitabine combined with ramucirumab. A 2025 ASCO-reported study showed gemcitabine-ramucirumab extended median survival from 7.5 to 13.8 months compared to gemcitabine alone (HR 0.71). Pemetrexed maintenance after first-line platinum-pemetrexed is not recommended per the 2025 ASCO guidelines.

For more detailed information, see Chemotherapy for Mesothelioma and Heated Chemotherapy (HITHOC and HIPEC).

How Does Immunotherapy Treat Mesothelioma?

Immunotherapy has fundamentally changed the mesothelioma treatment landscape, with two immunotherapy-based regimens now among the three FDA-approved first-line options.

Nivolumab + Ipilimumab (Opdivo + Yervoy)

The combination of the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab was approved on October 2, 2020, based on the CheckMate 743 trial — the first new systemic therapy for mesothelioma in 16 years. In 605 randomized patients, the combination achieved a median overall survival of 18.1 months versus 14.1 months for chemotherapy (HR 0.74).

Five-year follow-up data published in February 2026 demonstrated durable long-term benefit:

Endpoint	Nivolumab + Ipilimumab	Chemotherapy
5-Year Overall Survival	14%	6%
5-Year PFS	8%	0%
Ongoing Response at 5 Years	17%	0%
Non-Epithelioid 5-Year OS	12%	1%

The benefit was particularly striking in non-epithelioid disease, where immunotherapy achieved a five-year survival rate of 12% compared to just 1% with chemotherapy (HR 0.48).

Pembrolizumab + Chemotherapy (Keytruda + Chemo)

On September 17, 2024, the FDA approved pembrolizumab combined with pemetrexed and platinum chemotherapy as first-line treatment based on the KEYNOTE-483 trial. In 440 patients, the combination achieved a median OS of 17.3 months versus 16.1 months for chemotherapy alone, with a nearly doubled objective response rate (52% vs. 29%) and a 3-year survival rate of 25% vs. 17%.

This chemoimmunotherapy approach is particularly favored for epithelioid disease, where the higher response rate may provide faster symptomatic relief compared to immunotherapy alone.

Second-Line Immunotherapy

For patients who received first-line chemotherapy, the ASCO 2025 guidelines recommend either double-agent immunotherapy (nivolumab + ipilimumab) or single-agent nivolumab as second-line options. The CONFIRM trial demonstrated that single-agent nivolumab improved overall survival compared to placebo in pretreated patients (adjusted HR 0.69, p=0.009).

For more detailed information, see Immunotherapy for Mesothelioma and CheckMate 743 Trial.

How Does Radiation Therapy Treat Mesothelioma?

Radiation therapy for mesothelioma serves three primary roles: adjuvant therapy after surgery, a component of the neoadjuvant SMART protocol, and palliation of symptoms including pain and dyspnea.

Intensity-Modulated Radiation Therapy (IMRT)

IMRT is the most commonly used radiation technique for mesothelioma, delivering precisely shaped radiation beams that conform to the irregular pleural surface while limiting dose to adjacent organs. Adjuvant IMRT after P/D achieves median survival of 19-33 months across published series. Modern IMRT protocols with strict dose constraints (combined mean lung dose below 21 Gy) have reduced the rate of grade 3 or higher radiation pneumonitis from 46% to 7%.

Proton Beam Therapy

Proton therapy offers a dosimetric advantage over photon-based IMRT, delivering substantially less radiation to surrounding organs: mean heart dose of 6.0 Gy versus 25.0 Gy with IMRT, and contralateral lung dose of 0.4 Gy versus 4.6 Gy. A University of Pennsylvania series reported 0% grade 3 or higher pneumonitis in 16 patients treated to a median dose of 51.75 Gy.

The SMART Protocol

The Surgery for Mesothelioma After Radiation Therapy (SMART) protocol reverses the traditional sequence by delivering short-course neoadjuvant radiation (25 Gy in 5 fractions over one week) followed by EPP within days. Because the irradiated lung is removed surgically, the risk of radiation pneumonitis on the treated side is eliminated. In 96 eligible patients, the SMART protocol achieved a median survival of 36 months overall and 65.9 months in epithelioid node-negative patients.

Palliative Radiation

Palliative radiation (typically 20-36 Gy) is effective for managing mesothelioma symptoms. The SYSTEMS trial demonstrated that 20 Gy in 5 fractions achieved clinically significant pain reduction in 47% of assessable patients at 5 weeks with minimal toxicity. Higher-dose fractionation (4 Gy per fraction) achieves 50% local response rates compared to 39% for lower doses.

For more detailed information, see Radiation Therapy for Mesothelioma.

What Is Multimodal Treatment for Mesothelioma?

Multimodal therapy combines two or more treatment modalities (surgery, chemotherapy, immunotherapy, radiation) and represents the standard approach for patients eligible for curative-intent treatment. The specific combination and sequence depends on disease stage, histology, and institutional expertise.

Trimodal Therapy

The classical trimodal approach, pioneered by David Sugarbaker, combines EPP with chemotherapy and radiation. In 120 patients, this protocol achieved 22% five-year survival overall and 39% five-year survival in the optimal subgroup (epithelioid, node-negative). The De Perrot protocol (induction chemotherapy followed by EPP and radiation) achieved 59-month median survival in node-negative patients.

However, the ASCO 2025 guidelines no longer recommend routine trimodal therapy with EPP, instead favoring P/D-based approaches with chemotherapy and/or immunotherapy.

Perioperative Immunotherapy

A Johns Hopkins-led phase 2 trial investigated neoadjuvant nivolumab with or without ipilimumab before surgery. Patients receiving neoadjuvant nivolumab plus ipilimumab achieved a median OS of 28.6 months and median PFS of 19.8 months, with 85.7% proceeding to surgery. Circulating tumor DNA analysis demonstrated clinical utility for predicting surgical outcomes.

Treatment Sequencing by Histology

Histology	Recommended First-Line	Second-Line Options
Non-epithelioid (sarcomatoid/biphasic)	Ipilimumab + nivolumab (preferred); pembrolizumab + pemetrexed + platinum (alternative)	Pemetrexed + platinum; vinorelbine or gemcitabine
Epithelioid	Ipilimumab + nivolumab; pembrolizumab + pemetrexed + platinum; pemetrexed + platinum +/- bevacizumab	Nivolumab +/- ipilimumab (post-chemo); chemotherapy (post-immunotherapy)
Peritoneal	CRS-HIPEC (if resectable); systemic chemotherapy (if unresectable)	Systemic immunotherapy or chemotherapy

Source: ASCO 2025 Guidelines

What Emerging Therapies Are in the Pipeline?

ADI-PEG 20 (Pegargiminase) — Arginine Depletion Therapy

ADI-PEG 20 is a pegylated arginine deiminase that starves cancer cells of the amino acid arginine. Approximately 50% of mesotheliomas lack expression of argininosuccinate synthetase 1 (ASS1), making them dependent on exogenous arginine. The ATOMIC-Meso phase 2/3 trial in non-epithelioid patients demonstrated a median OS of 9.3 vs. 7.6 months (PFS HR 0.66, 34% risk reduction), with some patients surviving beyond three years. A Biologics License Application is under FDA review, with a decision expected by late 2026 or early 2027. If approved, ADI-PEG 20 would be the first metabolic therapy approved for mesothelioma. The ASCO 2025 guidelines already include a conditional recommendation for pegargiminase plus chemotherapy for non-epithelioid patients who cannot receive immunotherapy.

Tumor Treating Fields (TTFields / Optune Lua)

TTFields deliver alternating electric fields at 150 kHz to disrupt cancer cell division. The NovoTTF-100L device (Optune Lua) was approved via Humanitarian Device Exemption in May 2019 based on the STELLAR trial, which achieved a median OS of 18.2 months and a 97% disease control rate in 80 patients receiving TTFields with chemotherapy. Patients wear the portable device with transducer arrays on the thorax for a minimum of 18 hours per day. The principal side effect is mild-to-moderate skin reactions beneath the arrays, with no additional systemic toxicity.

The ASCO 2025 guidelines note insufficient evidence to recommend TTFields addition to chemotherapy, reflecting the limitation of the single-arm trial design.

CAR-T Cell Therapy

Chimeric antigen receptor T-cell therapy targeting mesothelin, a protein overexpressed on the majority of mesothelioma cells, represents one of the most promising emerging approaches. The most advanced program, led by Dr. Prasad Adusumilli at Memorial Sloan Kettering, uses intrapleurally delivered mesothelin-targeted CAR-T cells combined with pembrolizumab:

• 72% objective response rate in 11 mesothelioma patients (including 2 durable complete metabolic responses)
• 23.9-month median OS in the combination cohort
• Only grade 1-2 adverse events with no "on-target, off-tumor" toxicity
• A built-in safety "suicide switch" for emergency CAR-T cell destruction
• Phase II trial ongoing at MSK (NCT02414269)

Additional programs include gavocabtagene autoleucel (gavo-cel), a mesothelin-targeting T-cell receptor fusion construct that achieved 20% ORR and 77% disease control rate in a phase 1 trial (FDA Orphan Drug designation granted), and SynKIR-110, a next-generation KIR-based receptor system in early development.

Other Emerging Approaches

• ONCOS-102: A genetically modified oncolytic adenovirus that achieved 20.3-month median OS in first-line patients compared to 13.5 months in controls
• TargomiRs: Minicells loaded with miR-16-based mimic miRNA showed 1 partial response and 15 stable disease cases in 22 recurrent mesothelioma patients
• DREAM3R (Phase 3): Durvalumab + chemotherapy vs. chemotherapy vs. nivolumab + ipilimumab — ongoing, completion expected 2025-2026
• eVOLVE-meso (Phase 3): Volrustomig + carboplatin + pemetrexed vs. standard — ongoing

What Is Palliative Care for Mesothelioma?

Palliative care focuses on relieving symptoms and improving quality of life alongside active treatment. All major oncology organizations — WHO, ASCO, NCCN, and the British Thoracic Society — recommend early integration of palliative care beginning at or soon after diagnosis.

Evidence for Early Palliative Care

The landmark Temel (2010) randomized trial in metastatic non-small cell lung cancer demonstrated that early palliative care improved median survival by 2.7 months (11.6 vs. 8.9 months, p=0.02), improved quality of life scores, and reduced depression (16% vs. 38%, p=0.01). Patients receiving early palliative care also received less aggressive end-of-life treatment yet lived longer. A meta-analysis of 12 randomized trials (n=2,364) confirmed that early palliative care reduced mortality by 29% (OR 0.71, 95% CI: 0.51-0.99).

Symptom Management

Mesothelioma patients experience a significant symptom burden requiring active palliative management:

• Dyspnea: The cardinal symptom of pleural mesothelioma, managed with opioids, oxygen therapy, thoracentesis, pleurodesis, or indwelling pleural catheters
• Pain: Complex and multifactorial, including nociceptive and neuropathic components requiring multimodal analgesia (opioids, gabapentin/pregabalin, NSAIDs, nerve blocks)
• Pleural effusions: Managed with thoracentesis, talc pleurodesis, or tunneled pleural catheters — catheters reduce hospitalization days (median 10 vs. 12) and repeat procedures (4% vs. 22.5%)
• Fatigue and cachexia: Common and debilitating; exercise programs and nutritional support may help
• Psychological distress: Depression and anxiety occur at high rates; early psychological intervention is recommended

Palliative Care versus Hospice

Palliative care begins at diagnosis and runs alongside curative or life-prolonging treatment. Hospice care, by contrast, is a form of palliative care specifically for patients with a prognosis of six months or less who have chosen to forgo curative treatment. Studies consistently show that palliative care does not hasten death — it may actually extend survival.

How Does Treatment Differ by Stage?

Treatment approaches vary significantly based on disease stage at diagnosis:

Stage I (Localized Disease)

Patients with stage I disease confined to the pleural surface without lymph node involvement represent the best candidates for curative-intent multimodal therapy. Treatment typically involves neoadjuvant chemotherapy or immunotherapy followed by P/D and adjuvant radiation. Some centers offer the SMART protocol (neoadjuvant radiation followed by surgery) for this group.

Stage II-III (Locally Advanced Disease)

The majority of mesothelioma patients are diagnosed at stage II or III. Treatment options include systemic therapy (immunotherapy or chemotherapy) with or without surgery, depending on the extent of disease, lymph node involvement, histology, and patient fitness. Patients with T1-3N0 epithelioid disease may still be surgical candidates; those with N1-N2 disease or non-epithelioid histology are generally treated with systemic therapy alone.

Stage IV (Advanced/Metastatic Disease)

Patients with stage IV disease, including those with contralateral pleural involvement or distant metastases, are treated with systemic therapy. First-line options are nivolumab plus ipilimumab (preferred for non-epithelioid) or pembrolizumab plus chemotherapy. Palliative radiation may be used for symptomatic sites. Clinical trial enrollment is strongly encouraged.

Peritoneal Mesothelioma

Treatment for peritoneal mesothelioma follows a separate algorithm. Resectable disease is treated with CRS-HIPEC, which achieves median survival exceeding 53 months at experienced centers. Unresectable disease is treated with systemic chemotherapy (pemetrexed-platinum) or immunotherapy. The evidence base for peritoneal mesothelioma is more limited than for pleural, and most recommendations are extrapolated from pleural disease trials.

Where Are Leading Mesothelioma Treatment Centers?

Mesothelioma treatment requires specialized expertise. High-volume centers consistently achieve better outcomes than low-volume facilities — experienced centers report 10.0% 90-day mortality compared to 14.6% at low-volume centers, with shorter hospitalizations and fewer readmissions. More than 50 specialized mesothelioma treatment facilities operate across the United States, and 93 clinical trials were actively recruiting mesothelioma patients as of early 2026.

Patients should seek care at centers that offer:

• Multidisciplinary tumor boards with thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, and pathologists
• Access to clinical trials, including immunotherapy and cellular therapy studies
• High annual surgical volumes for mesothelioma
• Comprehensive supportive care including palliative medicine, pain management, and pulmonary rehabilitation

For a comprehensive list of facilities, see Mesothelioma Treatment Centers.

Frequently Asked Questions

What is the most effective treatment for mesothelioma?

The most effective treatment depends on disease stage, histologic subtype, and patient fitness. For non-epithelioid (sarcomatoid/biphasic) mesothelioma, nivolumab plus ipilimumab immunotherapy is the preferred first-line treatment, more than doubling five-year survival compared to chemotherapy. For epithelioid disease, immunotherapy, chemoimmunotherapy, or chemotherapy with bevacizumab are all recommended options. For peritoneal mesothelioma, CRS-HIPEC achieves the longest survival at experienced centers.

Can mesothelioma be cured?

Mesothelioma is considered incurable for most patients, but long-term survival is achievable. Five-year survival data show that 14% of immunotherapy patients and 6% of chemotherapy patients are alive at five years. Selected surgical patients achieve even longer survival — the SMART protocol produces 65.9-month median survival in optimal candidates, and CRS-HIPEC for peritoneal disease achieves 5-year survival rates of 47%.

What are the newest treatments for mesothelioma?

The newest FDA-approved treatment is pembrolizumab combined with pemetrexed and platinum chemotherapy, approved in September 2024. Emerging therapies include ADI-PEG 20 arginine depletion therapy (BLA under FDA review), mesothelin-targeted CAR-T cell therapy (72% response rate in early trials), and tumor treating fields (approved under HDE). Multiple phase 3 trials are ongoing, including DREAM3R and eVOLVE-meso.

How do I choose between immunotherapy and chemotherapy?

The 2025 ASCO guidelines recommend basing this decision primarily on histologic subtype. Non-epithelioid patients should receive immunotherapy first-line (ipilimumab + nivolumab preferred). Epithelioid patients have three options: immunotherapy alone, chemoimmunotherapy, or chemotherapy with or without bevacizumab. PD-L1 expression, tumor mutational burden, and microsatellite instability status should not be used to guide selection.

Is surgery still recommended for mesothelioma?

Surgery remains an option but is now restricted to highly selected patients. The 2025 ASCO guidelines recommend surgical cytoreduction only for early-stage (T1-3N0) epithelioid tumors at experienced centers, with P/D as the preferred approach over EPP. Surgery is explicitly not recommended for sarcomatoid disease. For peritoneal mesothelioma, CRS-HIPEC remains the standard of care when complete cytoreduction is feasible.

Quick Statistics

• 14% five-year overall survival with nivolumab plus ipilimumab versus 6% with chemotherapy in the CheckMate 743 trial
• 3 FDA-approved systemic regimens for pleural mesothelioma as of 2026 (cisplatin-pemetrexed, nivolumab-ipilimumab, pembrolizumab-chemo)
• 93 clinical trials actively recruiting mesothelioma patients as of early 2026, with 52 based in the United States
• 53-month median survival with CRS-HIPEC for peritoneal mesothelioma, versus approximately 12 months with systemic chemotherapy alone
• 72% response rate with mesothelin-targeted CAR-T cells plus pembrolizumab in early-phase mesothelioma trials
• 110 studies reviewed for the 2025 ASCO guideline update, the most comprehensive revision since 2018
• 7-month survival advantage for P/D over EPP in a 2025 systematic review and meta-analysis of 24 studies
• 97% disease control rate with TTFields plus chemotherapy in the STELLAR trial
• 50%+ of mesotheliomas lack ASS1 expression, making them candidates for arginine depletion therapy
• 2.7-month survival benefit with early palliative care integration in the Temel landmark lung cancer trial

Get Help

Danziger & De Llano — Experienced mesothelioma attorneys providing free case reviews and helping families secure compensation for treatment costs. Call (855) 699-5441. Mesothelioma Lawyers Near Me — Connect with qualified mesothelioma attorneys in your area for legal assistance. Mesothelioma.net — Comprehensive patient resource with treatment information and support. MesotheliomaAttorney.com — Legal resources for mesothelioma patients and families.

Related Pages

• Immunotherapy for Mesothelioma
• Chemotherapy for Mesothelioma
• Radiation Therapy for Mesothelioma
• Mesothelioma Surgery Overview
• Mesothelioma Surgery Recovery
• Heated Chemotherapy (HITHOC and HIPEC)
• Mesothelioma Treatment Centers
• Mesothelioma Treatment Costs
• Mesothelioma Clinical Trials
• Pleural Mesothelioma
• Peritoneal Mesothelioma
• Mesothelioma Types and Histology
• Asbestos Health Effects
• Mesothelioma Settlements

Free, Confidential Case Evaluation Call (855) 699-5441 or visit dandell.com/contact-us No upfront fees • Experienced representation • National practice